C.R. Bard, Inc. (NYSE:BCR) hit a new 52-week high during trading on Tuesday . The stock traded as high as $336.46 and last traded at $333.29, with a volume of 589900 shares. The stock had previously closed at $333.56.

Several equities research analysts have recently commented on BCR shares. Zacks Investment Research upgraded shares of C.R. Bard from a “hold” rating to a “buy” rating and set a $360.00 price target for the company in a research report on Monday, July 31st. Barclays PLC lifted their price target on shares of C.R. Bard from $245.00 to $337.00 and gave the stock an “equal weight” rating in a research report on Monday, November 6th. Jefferies Group LLC reiterated a “hold” rating on shares of C.R. Bard in a research report on Thursday, August 3rd. Cowen and Company reiterated a “hold” rating and set a $317.00 price target on shares of C.R. Bard in a research report on Friday, November 3rd. Finally, Needham & Company LLC reiterated a “hold” rating on shares of C.R. Bard in a research report on Thursday, October 26th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $303.50.

The firm has a market capitalization of $24,539.94, a price-to-earnings ratio of 29.07, a PEG ratio of 2.57 and a beta of 0.53. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.37 and a current ratio of 1.72.

C.R. Bard (NYSE:BCR) last issued its quarterly earnings data on Wednesday, October 25th. The medical instruments supplier reported $3.02 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.96 by $0.06. The firm had revenue of $989.80 million during the quarter, compared to analysts’ expectations of $990.64 million. C.R. Bard had a net margin of 14.75% and a return on equity of 48.28%. The business’s revenue for the quarter was up 5.1% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.64 earnings per share. equities research analysts predict that C.R. Bard, Inc. will post 11.89 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 29th. Investors of record on Friday, December 8th will be issued a dividend of $0.26 per share. This represents a $1.04 dividend on an annualized basis and a yield of 0.31%. The ex-dividend date is Thursday, December 7th. C.R. Bard’s dividend payout ratio is currently 13.70%.

In other C.R. Bard news, Director David M. Barrett sold 3,344 shares of C.R. Bard stock in a transaction that occurred on Monday, October 30th. The shares were sold at an average price of $327.31, for a total value of $1,094,524.64. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Vice Chairman John H. Weiland sold 33,435 shares of C.R. Bard stock in a transaction that occurred on Tuesday, November 7th. The shares were sold at an average price of $333.31, for a total transaction of $11,144,219.85. Following the completion of the transaction, the insider now directly owns 76,331 shares in the company, valued at approximately $25,441,885.61. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 191,593 shares of company stock valued at $62,655,513. Corporate insiders own 0.80% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the business. Monroe Bank & Trust MI lifted its stake in C.R. Bard by 65.6% in the third quarter. Monroe Bank & Trust MI now owns 447 shares of the medical instruments supplier’s stock valued at $100,000 after buying an additional 177 shares in the last quarter. Patten Group Inc. lifted its stake in C.R. Bard by 66.0% in the third quarter. Patten Group Inc. now owns 556 shares of the medical instruments supplier’s stock valued at $106,000 after buying an additional 221 shares in the last quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. lifted its stake in C.R. Bard by 70.4% in the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 460 shares of the medical instruments supplier’s stock valued at $145,000 after buying an additional 190 shares in the last quarter. Parallel Advisors LLC lifted its stake in C.R. Bard by 2.8% in the second quarter. Parallel Advisors LLC now owns 513 shares of the medical instruments supplier’s stock valued at $164,000 after buying an additional 14 shares in the last quarter. Finally, Valeo Financial Advisors LLC bought a new position in C.R. Bard in the third quarter valued at approximately $170,000. 80.31% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “C.R. Bard, Inc. (BCR) Reaches New 12-Month High at $336.46” was published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be viewed at https://theolympiareport.com/2017/11/23/c-r-bard-inc-bcr-reaches-new-12-month-high-at-336-46.html.

About C.R. Bard

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.